A Study of Real-Life Current Standards of Care in Participants With Relapsed and/or Refractory Multiple Myeloma
Condition(s):Relapsed/Refractory Multiple MyelomaLast Updated:February 28, 2024Active, not recruiting
Hide Studies Not Open or Pending
Condition(s):Relapsed/Refractory Multiple MyelomaLast Updated:February 28, 2024Active, not recruiting
Condition(s):Relapsed/Refractory Multiple Myeloma(MM)Last Updated:March 15, 2024Terminated
Condition(s):Refractory Multiple Myeloma; Relapsed Multiple MyelomaLast Updated:March 12, 2024Recruiting
Condition(s):Relapsed/Refractory Multiple Myeloma (RRMM)Last Updated:February 29, 2024Recruiting
Condition(s):Relapsed or Refractory Multiple MyelomaLast Updated:December 11, 2019Unknown status
Condition(s):Light Chain Deposition Disease; Refractory Plasma Cell MyelomaLast Updated:April 15, 2015Completed
Condition(s):Recurrent Plasma Cell Myeloma; Refractory Plasma Cell MyelomaLast Updated:November 4, 2020Completed
Condition(s):Relapsed and Refractory Multiple MyelomaLast Updated:February 5, 2021Completed
Condition(s):Relapsed Multiple Myeloma; Refractory Multiple MyelomaLast Updated:May 4, 2022Withdrawn
Condition(s):Recurrent Plasma Cell Myeloma; Refractory Plasma Cell MyelomaLast Updated:December 8, 2022Terminated
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.